Factors Affecting the Price of Epclusa
The efficacy of EPCLUSA in children 3 years and older is supported by clinical trials. In one study, treatment-naïve and treatment-experienced pediatric subjects with genotypes 1, 2, 3, 4, or 6 HCV received EPCLUSA for 12 weeks. The safety and effectiveness observed in these pediatric subjects were comparable to those seen in adult patients, demonstrating high sustained virologic response rates.
